Wedbush Initiates Coverage On Larimar Therapeutics with Outperform Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has initiated coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Outperform rating and set a price target of $22.
October 03, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush has initiated coverage on Larimar Therapeutics with an Outperform rating and a price target of $22, suggesting potential upside.
The initiation of coverage with an Outperform rating and a specific price target of $22 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100